35 results about "Androgen level" patented technology

The present invention provides compositions and methods for treating QT prolongation in a subject in need thereof. The method comprises the step of administering to the subject a therapeutically effective amount of an agent which increases the androgen level of the subject.

A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months. A method of increasing the rate and number of euploid oocytes may include administering an androgen for at least about four consecutive weeks. In addition, a method of increasing male fetus sex ratio may comprise raising baseline androgen levels in a female prior to or at time of embryo implantation.

The invention discloses an application of baicalin in preparation of a medicine for treating polycystic ovarian syndrome. As shown in an in vivo experiment, the baicalin has obvious treatment effect on a polycystic ovarian syndrome rat model and can greatly reduce the high androgen level of the rat model, promote follicle maturity and induce ovulation; as shown in an in vitro experiment, the baicalin can inhibit the expression of androgen of a polycystic ovarian syndrome cell model. More importantly, the baicalin has small side effect and incomparable security while having no liver and kidney toxicity. Therefore, the baicalin can be used for preparing the medicine for treating polycystic ovarian syndrome and has a brilliant prospect.

The invention discloses a traditional Chinese medicine monomer composition for preparation of drugs used for treating polycystic ovarian syndrome. The invention is characterized in that the traditional Chinese medicine monomer composition comprises, by mass, 2 to 4% of cryptotanshinone, 13 to 18% of baicalin, 7 to 10% of quercetin and 65 to 80% of adjuvants, wherein the percentages of the above-mentioned components sum to 100%. According to results of in vivo experiments, combined application of the three traditional Chinese medicine monomers consisting of cryptotanshinone, baicalin and quercetin exerts an obvious therapeutic effect on the polycystic ovarian syndrome of a rat model and can substantially increase the level of androgen, promote maturation of ovarian follicles and induce ovulation. More importantly, the three traditional Chinese medicine monomers have no toxicity to the liver and the kidney, little side effects and incomparable security. Thus, the traditional Chinese medicine monomer composition provided by the invention can be used for preparing the drugs used for treating the polycystic ovarian syndrome and has good prospects.

The androgen receptor (AR) is the key driver of prostate differentiation and prostate cancer (PC) progression, and androgen ablation is the cornerstone of advanced PC treatment. Prostate-specific membrane antigen (PSMA) represents another target of interest in PC. Previous publications have reported inconsistent associations between androgen levels and PSMA expression. Using a panel of prototypical human PC cell lines, this relationship is clarified. PSMA is a biomarker that distinguishes AR-positive/PSMA-positive adenocarcinomas from AR-negative variants. PSMA is a cell surface barometer of androgen activity that can be readily identified by immunohistochemistry and/or in vivo imaging. Given that anti-androgen therapy is likely to remain a cornerstone of PC treatment, the associated up-regulation of PSMA, as well as its other characteristics, makes it a compelling target opportunity in PC.

The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or a functional analogue thereof that lowers the effective dose of the chemotherapeutic agent, such as for example, paclitaxel.

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.

The invention discloses application of cyanidin-3-O-glucoside in preparation of drugs for treating and/or preventing hormonal disorder diseases. It is found that the cyanidin-3-O-glucoside can improvethe androgen secretion disorder caused by Cd exposure during puberty, and the hypothalamus-pituitary-gonad axis can be protected from injuries caused by the Cd exposure. According to C3G intervention, the synthesis and secretion of hypothalamic gonadotropin releasing hormones, the expression of pituitary and testicular sex hormone receptors and the expression of testosterone synthesis pathway-related proteins in the testis can be intervened, so that the testosterone concentration returns to a normal level, the androgen level in the inner environment of the testis is maintained accordingly, and the generation of sperms is promoted. The application provides a theoretical basis for future research on the nutrition intervention of anthocyanins with the Cd reproductive toxicity and has an important significance.

The invention provides a traditional Chinese medicine drug for treating polycystic ovarian syndrome. The traditional Chinese medicine drug is prepared from processed radix aconiti lateralis, cortex cinnamomi, morinda officinalis, cistanche, crystobalite, tortoise-plastron glue, prepared rehmannia roots, dogwood, dodder, fruits of Chinese wolfberry, cornu cervi degelatinatum, roasted rhizoma atractylodis macrocephalae, poria cocos, rhizoma pinellinae praeparata, salvia miltiorrhiza, angelica sinensis, motherwort fruits, radix paeoniae alba, fructus psoraleae, fructus aurantii and honey-fried licorice roots. The curative effect is remarkable, the androgen level can be effectively lowered, inhibition of follicular development is relieved, and the ovulation function is recovered.

Biologically active dietary supplements (BADS) are proposed for normalizing the hormone balance and the overall condition in men based on natural ingredients. The BADS contain white cinquefoil roots and rhizomes or the above-ground part of white cinquefoil, or a mixture thereof, as well as drone brood in a quantity of from 20 mass % to 80 mass %. The disclosure makes it possible to produce a product which demonstrates, by virtue of an optimally selected ratio of ingredients, a synergistic effect in relation to the normalization of the androgen level and the prophylaxis of obesity in men.

Sexual wellness or sexual fitness is enhanced over time by administrating on a daily basis a source of proanthocyanidins and a source of arginine. Both sources may be blended into a composition or taken separately from a kit. The source of arginine may be a salt or peptide of L-arginine and aspartic acid such as arginine aspartate. The proanthocyanidins stimulate an endothelial NO-synthase enzyme, which serves as a catalyst for synthesis of the nitric oxide from a substration that is the source of the arginine. A sufficient amount of the nitric oxide is released over time to enhance sexual wellness or sexual fitness. In case of low levels of androgenic hormones in both sexes, the combination may contain as a further ingredient a sex hormone or a sex hormone precursor or a sex hormone stimulant or a sex hormone bioavailability enhancer.

The invention belongs to the technical field of medical information and discloses an information acquisition system for a joint marker for diagnosing PCOS (polycystic ovarian syndrome). The information acquisition system for the joint marker for diagnosing the PCOS comprises an excessive androgen measurement module, a serum extraction module, a central control module, a joint marker testing module, a treatment module, a data storage module and a display module. A detection kit can realize high-sensitivity and efficient detection and has the characteristics of low detection cost and good repeatability. Meanwhile, pharmaceutical composition provided by the treatment module and used for the excessive androgen type PCOS comprises medicinal materials including herba epimedii, fritillaria, fructus psoraleae, antler slices, hippocampus, tortoise plastron and the like, does not contain radix et rhizoma rhei or radix angelicae sinensis, notably reduces the androgen level of a patient, improvesgrowth of ovarian follicle and increases the ovulation rate and the pregnancy rate of the patient in the child-bearing period after being taken for a period of time.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including cyclic and heterocyclic anilide rings and their synthetic precursors, and mono-, di-, or multi-substituted N-heterocyclic rings, R-isomers, non-hydroxylated and/or non-chiral propanamides in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

The invention provides a natural efficient anti-hair-loss hair restorer. A formula of the natural efficient anti-hair-loss hair restorer comprises cannabidiol crude oil, Morocco nut oil, frankincenseoil, tea tree oil, castor oil, bergamot oil and cannabis oil. Raw materials are weighed according to the formula, the raw materials are put into a mixing kettle to be stirred for 10-15 minutes at thetemperature of 35-39 DEG C to enable the raw materials to be in a homogenate state, still standing is conducted for two hours to obtain the natural efficient anti-hair-loss hair restorer, and bottlingis conducted by using a rubber head dropper tool. The natural efficient anti-hair-loss hair restorer is prepared by taking the cannabidiol crude oil as the main raw material, cannabidiol acts on receptors such as the CB1 receptor, the TRPV1 receptor and the 5-HT1A receptor in a human body, thus the activity of 5-alpha reductase is inhibited advantageously, androgen can be generated after the 5-alpha reductase is controlled to react with and testosterone in the human body, and thus the aim of treating alopecia is fulfilled by reducing the androgen level.

The present invention provides a polypeptide comprising an estrogen or androgen binding region, the binding region capable of binding to an estrogen or androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available estrogen or androgen is decreased. The invention also provides for the treatment or prevention of cancers such as ovarian cancer, breast cancer and endometrial cancer using the polypeptides.

The present invention relates to an application of sulfur in preparation of a composition for increasing testosterone level or improving intestinal flora. The invention reveals for the first time thatthe sulfur has the effects of increasing the testosterone level and improving the intestinal flora. The invention provides a new way for researching a new medicine for improving the androgen level and a new medicine for improving the intestinal flora.

A method for the use of derivatives of hydroxypregnenolone (3-beta,17-alpha-dihydroxypregn-5-en-3-one) to enhance health and physical performance in humans and more particularly to the use of hydroxypregnenolone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function.

The invention discloses application of prinsepia utilis royle in an anti-benign prostatic hyperplasia drug. Leaves of prinsepia utilis royle are dried under the temperature of 40 DEG C to constant weight, the leaves of prinsepia utilis royle are soaked into water with the weight being 8-16 times that of the leaves of prinsepia utilis royle for 0.5-1 h, reflux extraction is performed for 1-2 h, after filtering is performed through three-layer gauze, filtering is performed through a 100-mesh screen cloth, water with the weight being 8-14 times that of medicinal materials is added into residues to be subjected to reflux extraction, medicine liquid is filtered out, and filtrates are combined. The prinsepia utilis royle extract can treat hyperplasia of prostate, improve the estrogen/androgen proportion mainly by lowering the androgen level and enhance the body oxidation resistance.

A method of improving sexual function in premenopausal women, who have low Female Sexual Function Index (FSFI) baseline of less than or equal to 25.7. The method includes providing information to premenopausal women to provide input for calculating the FSFI score and, if the score is low, providing dehydroepiandrosterone (DHEA) supplementation to be taken in 25 mg dosages daily once, twice, thrice or four times over a period of time of four to six weeks. By the end of the period of time, the FSFI baselines of the premenopausal women improves by at least seven percent, serum androgen levels of the premenopausal women increase and follicle-stimulating hormone (FSH) levels of the premenopausal women decrease.

A method for the use of derivatives of hydroxyprogesterone (17-alpha-hydroxypregn-4-ene-3,20-dione) to enhance health and physical performance in humans and more particularly to the use of hydroxyprogesterone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function.

The invention discloses an application of Tempol in preparation of a medicine for treating polycystic ovarian syndrome, animal experiments discover that Tempol can reduce the androgen level of mammals, recover the ovulation function of mammals, improve the polycystic change of ovaries, relieve the change of intestinal flora and relieve the difference change of serum metabolites for the first time,then PCOS can be obviously improved and a significant curative effect is obtained. The invention provides a new technical means for the treatment of PCOS, has very important significance for the clinical treatment and/or adjuvant therapy of PCOS, and has wide application prospects.

The invention discloses a novel application of berberine. The invention relates to application of berberine or derivatives or pharmaceutically acceptable salts thereof in preparation of drugs for improving androgen. The berberine or the derivative or the pharmaceutically acceptable salt thereof is applied to preparation of drugs for treating diseases caused by insufficient androgen secretion. The influence of berberine on androgen is discussed through a clinical random control test in Chinese male for the first time. Firstly, very strong innovativeness is acieved, i.e., the first clinical random control test research for detecting the effect of berberine on male androgen level; the gold standard of the clinical random control test is adopted to clarify the effect of the berberine on the androgen, such that the berberine has the androgen increasing effect, and can be used for preparing the androgen increasing drug, or can be used for treating the diseases caused by the insufficient androgen secretion.